Jiangxi Jemincare Group Launches Omalizumab Biosimilar CMAB007 in China for Asthma and Dermatology
Jiangxi Jemincare Group has overseen the official launch and first prescription of its omalizumab biosimilar,...
Drug
C4 Therapeutics’ CFT8919 Earns FDA Approval for Clinical Trials Targeting EGFR L858R Mutations
US-based C4 Therapeutics Inc., (NASDAQ: CCCC) has announced receiving clinical trial approval from the US...
Zai Lab’s Vyvgart Receives NMPA Review for Subcutaneous Injection Form in gMG Treatment
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced that the National Medical Products...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-9815 Radiodiagnostic Drug Clinical Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval...
Transcenta Holding Ltd Secures Global Clinical Trial Approvals for Osemitamab in Gastric Cancer
China-based Transcenta Holding Ltd has reported receiving clinical trial approvals from China’s Center for Drug...
Shanghai BDgene Technology Receives US FDA Approval for HSV-1 Stromal Keratitis Gene Therapy
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced receiving approval from the US...
HutchMed Ltd Initiates Phase I Clinical Study for SHP2 Inhibitor HMPL-415 in Solid Tumors
China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced the initiation of a Phase I...
Shanghai Fosun Pharmaceutical Submits Daxibotulinumtoxin A (RT002) for NMPA Approval
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-1703 Clinical Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval...
3SBio Inc. Receives NMPA Approval for Nalfurafine Tablets to Treat Hemodialysis-Related Pruritus
China-based 3SBio Inc. (HKG: 1530) has announced receiving marketing approval from the National Medical Products...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Esflurbiprofen Patch Clinical Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
CSPC Pharmaceutical Group Receives Marketing Approval for Desvenlafaxine in China
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving marketing approval in China for...
AbbVie’s Rinvoq Receives NMPA Approval for Moderate to Severe Crohn’s Disease Treatment
US pharmaceutical firm AbbVie (NYSE: ABBV) has announced receiving market approval from the National Medical...
Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
Huadong Medicine’s Liraglutide Biosimilar Gains NMPA Approval for Weight Loss Indication
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received additional indication...
Abbisko Therapeutics’ EGFR Inhibitor ABSK112 Clears FDA for Global Phase I NSCLC Study
Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
Jacobio Pharma’s KRAS Inhibitor Glecirasib Advances to Pivotal Pancreatic Cancer Trial
China-based Jacobio Pharma (HKG: 1167) has announced that it has received the green light from...
InnoCare Pharma Initiates Clinical Trial for TYK2 Inhibitor ICP-488 in Psoriasis Patients
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced a significant milestone in the clinical...
NMPA Approves Pitolisant for Narcolepsy-Related Excessive Daytime Drowsiness and Cataplexy
The National Medical Products Administration (NMPA) has approved pitolisant as a treatment for excessive daytime...
Ascentage Pharma’s Olverembatinib Gets NMPA Greenlight for Phase III Study in Ph+ ALL
China-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the National...